接受古舍库单抗治疗的恶性肿瘤和中度-重度银屑病患者的真实世界结局

JAAD International Pub Date : 2024-04-07 DOI:10.1016/j.jdin.2024.02.019

Tamara Gracia Cazaña MD, PhD , Josep Riera Monroig MD , Rosa Izu MD, PhD , Ignacio Yanguas MD, PhD , Marta Lorda Espés MD, PhD , María Pilar Sánchez Salas MD , Miguel Fernando García Gil MD , Alba Navarro Bielsa MD , Beatriz Aldea Manrique MD , Manuel Almenara Blasco MD , Francisco Javier García-Latasa de Araníbar MD, PhD , Victoria Fuentelsaz MD, PhD , Ana Morales Callaghan MD, PhD , Mariano Ara-Martín MD, PhD

{"title":"接受古舍库单抗治疗的恶性肿瘤和中度-重度银屑病患者的真实世界结局","authors":"Tamara Gracia Cazaña MD, PhD , Josep Riera Monroig MD , Rosa Izu MD, PhD , Ignacio Yanguas MD, PhD , Marta Lorda Espés MD, PhD , María Pilar Sánchez Salas MD , Miguel Fernando García Gil MD , Alba Navarro Bielsa MD , Beatriz Aldea Manrique MD , Manuel Almenara Blasco MD , Francisco Javier García-Latasa de Araníbar MD, PhD , Victoria Fuentelsaz MD, PhD , Ana Morales Callaghan MD, PhD , Mariano Ara-Martín MD, PhD","doi":"10.1016/j.jdin.2024.02.019","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The treatment of psoriasis in patients with a personal history of cancer is a matter of debate and limited evidence is available to guide clinicians.</p></div><div><h3>Objectives</h3><p>To report a multicenter real-life experience of a group of patients with psoriasis undergoing treatment with guselkumab and a history of cancer.</p></div><div><h3>Methods</h3><p>We conducted a multicenter retrospective Spanish study enrolling patients with moderate-to-severe plaque psoriasis and neoplasia being treated with guselkumab for their psoriasis.</p></div><div><h3>Results</h3><p>Twenty patients with moderate-to-severe psoriasis and at least 12 weeks of ongoing treatment were included. For the analysis, a 52 week follow-up period was evaluated in terms of efficacy and safety. Most of the malignancies in these patients were solid tumors. The percentage of patients achieving psoriasis area and severity index ≤3 at week 12 and week 52 was 80% and 87.5%, respectively, whereas 68.8% of patients achieved psoriasis area and severity index ≤1. A 52-week survival rate of 100% in the study population was observed (<em>n</em> = 20), including those patients with concomitant active cancers (<em>n</em> = 14). No adverse effects or dropouts related to guselkumab safety profile were detected.</p></div><div><h3>Limitations</h3><p>Modest sample size and the retrospective nature of the study.</p></div><div><h3>Conclusion</h3><p>Guselkumab not only demonstrates high effectiveness in treating psoriasis but also exhibits a favorable safety profile in patients with neoplasms.</p></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"16 ","pages":"Pages 66-71"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666328724000580/pdfft?md5=3cbb5bbe8029dfc2b8d1e7a491ebd476&pid=1-s2.0-S2666328724000580-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab\",\"authors\":\"Tamara Gracia Cazaña MD, PhD , Josep Riera Monroig MD , Rosa Izu MD, PhD , Ignacio Yanguas MD, PhD , Marta Lorda Espés MD, PhD , María Pilar Sánchez Salas MD , Miguel Fernando García Gil MD , Alba Navarro Bielsa MD , Beatriz Aldea Manrique MD , Manuel Almenara Blasco MD , Francisco Javier García-Latasa de Araníbar MD, PhD , Victoria Fuentelsaz MD, PhD , Ana Morales Callaghan MD, PhD , Mariano Ara-Martín MD, PhD\",\"doi\":\"10.1016/j.jdin.2024.02.019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The treatment of psoriasis in patients with a personal history of cancer is a matter of debate and limited evidence is available to guide clinicians.</p></div><div><h3>Objectives</h3><p>To report a multicenter real-life experience of a group of patients with psoriasis undergoing treatment with guselkumab and a history of cancer.</p></div><div><h3>Methods</h3><p>We conducted a multicenter retrospective Spanish study enrolling patients with moderate-to-severe plaque psoriasis and neoplasia being treated with guselkumab for their psoriasis.</p></div><div><h3>Results</h3><p>Twenty patients with moderate-to-severe psoriasis and at least 12 weeks of ongoing treatment were included. For the analysis, a 52 week follow-up period was evaluated in terms of efficacy and safety. Most of the malignancies in these patients were solid tumors. The percentage of patients achieving psoriasis area and severity index ≤3 at week 12 and week 52 was 80% and 87.5%, respectively, whereas 68.8% of patients achieved psoriasis area and severity index ≤1. A 52-week survival rate of 100% in the study population was observed (<em>n</em> = 20), including those patients with concomitant active cancers (<em>n</em> = 14). No adverse effects or dropouts related to guselkumab safety profile were detected.</p></div><div><h3>Limitations</h3><p>Modest sample size and the retrospective nature of the study.</p></div><div><h3>Conclusion</h3><p>Guselkumab not only demonstrates high effectiveness in treating psoriasis but also exhibits a favorable safety profile in patients with neoplasms.</p></div>\",\"PeriodicalId\":34410,\"journal\":{\"name\":\"JAAD International\",\"volume\":\"16 \",\"pages\":\"Pages 66-71\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666328724000580/pdfft?md5=3cbb5bbe8029dfc2b8d1e7a491ebd476&pid=1-s2.0-S2666328724000580-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAAD International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666328724000580\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAAD International","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666328724000580","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

背景对有癌症病史的银屑病患者的治疗存在争议，可用于指导临床医生的证据有限。目的报告一组接受古舍库单抗治疗且有癌症病史的银屑病患者的多中心真实经历。方法我们开展了一项西班牙多中心回顾性研究，纳入了正在接受古舍库单抗治疗的中重度斑块状银屑病和肿瘤患者。在分析中，对随访 52 周的疗效和安全性进行了评估。这些患者的恶性肿瘤多为实体瘤。在第12周和第52周，牛皮癣面积和严重程度指数≤3的患者比例分别为80%和87.5%，而68.8%的患者牛皮癣面积和严重程度指数≤1。研究人群的52周存活率为100%（n=20），其中包括同时患有活动性癌症的患者（n=14）。结论古舍库单抗不仅治疗银屑病效果显著，而且对肿瘤患者也具有良好的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab

Background

The treatment of psoriasis in patients with a personal history of cancer is a matter of debate and limited evidence is available to guide clinicians.

Objectives

To report a multicenter real-life experience of a group of patients with psoriasis undergoing treatment with guselkumab and a history of cancer.

Methods

We conducted a multicenter retrospective Spanish study enrolling patients with moderate-to-severe plaque psoriasis and neoplasia being treated with guselkumab for their psoriasis.

Results

Twenty patients with moderate-to-severe psoriasis and at least 12 weeks of ongoing treatment were included. For the analysis, a 52 week follow-up period was evaluated in terms of efficacy and safety. Most of the malignancies in these patients were solid tumors. The percentage of patients achieving psoriasis area and severity index ≤3 at week 12 and week 52 was 80% and 87.5%, respectively, whereas 68.8% of patients achieved psoriasis area and severity index ≤1. A 52-week survival rate of 100% in the study population was observed (n = 20), including those patients with concomitant active cancers (n = 14). No adverse effects or dropouts related to guselkumab safety profile were detected.